Company recalls skin treatment products
Framingham, Mass. — A compounding pharmacy at the center of a national outbreak of fungal meningitis has voluntarily recalled all of its products, including numerous drugs for treating skin conditions.
After the Food and Drug Administration linked a fungal meningitis outbreak to a contaminated batch of steroid injections made at the New England Compounding Center, the company voluntarily recalled all drugs it manufactured. These products include many that are commonly used to treat skin conditions, including benzocaine, lidocaine, tetracaine, glycolic acid solutions, and salicylic acid solutions, among others.
The FDA has a full list of the recalled products on its website.
The outbreak prompted the American Society for Dermatologic Surgery Association to urge federal and state regulatory authorities to re-examine their oversight and enforcement of compounding pharmacies, according to a news release.
"Providing uncontaminated drugs at consistent, appropriate dosage levels must be of paramount concern," Timothy C. Flynn, M.D., ASDSA president, is reported as saying. "We are seeing too many cases of patients becoming ill or dying due to lack of appropriate oversight of compounded pharmacies."
Go back to the Dermatology Times eNews newsletter.
MORE ARTICLES IN THIS ISSUE
A recent study links psoriasis with an increased incidence of diabetes.
Propranolol may be more effective than corticosteroids in treating infantile cutaneous hemangiomas, a new study suggests.
Spending on medications for age-related conditions such as aging skin, hair loss, mental alertness and sexual dysfunction ranked third in annual prescription drug costs of the commercially insured in 2011, according to a recent study.
Sun Pharmaceutical Industries, based in India, will acquire DUSA Pharmaceuticals, aiming to advance into the dermatologic market in the United States.